Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1'-CN-4-aza-7,9-dideazaadenosine C-nucleoside

Signal Transduct Target Ther. 2023 Jan 12;8(1):27. doi: 10.1038/s41392-023-01310-0.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19*
  • Humans
  • Nucleosides
  • Prodrugs* / pharmacology
  • SARS-CoV-2

Substances

  • Nucleosides
  • Prodrugs
  • Antiviral Agents

Associated data

  • ClinicalTrials.gov/NCT05504746
  • ChiCTR/ChiCTR2200064093